UY36077A - Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen - Google Patents
Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienenInfo
- Publication number
- UY36077A UY36077A UY0001036077A UY36077A UY36077A UY 36077 A UY36077 A UY 36077A UY 0001036077 A UY0001036077 A UY 0001036077A UY 36077 A UY36077 A UY 36077A UY 36077 A UY36077 A UY 36077A
- Authority
- UY
- Uruguay
- Prior art keywords
- pteridin
- ona
- modulators
- derivatives
- amino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
- C07D475/10—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with an aromatic or hetero-aromatic ring directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención comprende compuestos de la fórmula (I) en donde las variables se definen en la presente que son apropiadas para la modulación de RORy y el tratamiento de enfermedades relacionadas con la modulación de RORy. La presente invención también comprende procesos de preparación de compuestos de la fórmula (I) y preparaciones farmacéuticas que los contienen.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461979231P | 2014-04-14 | 2014-04-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY36077A true UY36077A (es) | 2015-10-30 |
Family
ID=52998264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001036077A UY36077A (es) | 2014-04-14 | 2015-04-13 | Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen |
Country Status (36)
Country | Link |
---|---|
US (5) | US9242989B2 (es) |
EP (2) | EP3418280B1 (es) |
JP (2) | JP6282759B2 (es) |
KR (2) | KR102410076B1 (es) |
CN (3) | CN106132965B (es) |
AP (1) | AP2016009403A0 (es) |
AR (2) | AR100058A1 (es) |
AU (2) | AU2015247983B2 (es) |
BR (2) | BR122020020657B1 (es) |
CA (1) | CA2944787C (es) |
CL (1) | CL2016002421A1 (es) |
CY (1) | CY1122012T1 (es) |
DK (1) | DK3131902T3 (es) |
EA (2) | EA035063B1 (es) |
ES (1) | ES2744299T3 (es) |
HK (2) | HK1244801A1 (es) |
HR (1) | HRP20191579T1 (es) |
HU (1) | HUE045847T2 (es) |
IL (2) | IL247419B (es) |
LT (1) | LT3131902T (es) |
MA (1) | MA46373A (es) |
ME (1) | ME03513B (es) |
MX (1) | MX370780B (es) |
MY (1) | MY182834A (es) |
NZ (1) | NZ723530A (es) |
PE (2) | PE20161572A1 (es) |
PH (2) | PH12016502019B1 (es) |
PL (1) | PL3131902T3 (es) |
PT (1) | PT3131902T (es) |
RS (1) | RS59170B1 (es) |
SG (1) | SG11201608537SA (es) |
SI (1) | SI3131902T1 (es) |
TW (2) | TWI655192B (es) |
UA (2) | UA121255C2 (es) |
UY (1) | UY36077A (es) |
WO (1) | WO2015160654A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20161572A1 (es) * | 2014-04-14 | 2017-02-01 | Boehringer Ingelheim Int | Compuestos como moduladores de ror gamma |
FR3030518B1 (fr) * | 2014-12-19 | 2018-03-23 | Galderma Research & Development | Derives sulfonamides en tant qu'agonistes inverses du recepteur gamma orphelin associe aux retinoides ror gamma (t) |
CA2985547C (en) | 2015-05-15 | 2024-02-20 | Aurigene Discovery Technologies Limited | Substituted tetrahydroquinolinone compounds as ror gamma modulators |
EP3356366B1 (en) * | 2015-10-01 | 2019-08-28 | Boehringer Ingelheim International GmbH | Pteridine derivatives as modulators of ror gamma |
MX2018007296A (es) | 2015-12-15 | 2019-01-10 | Astrazeneca Ab | Compuestos de isoindol. |
US11358967B2 (en) | 2016-01-20 | 2022-06-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma |
TWI705958B (zh) | 2016-12-05 | 2020-10-01 | 荷蘭商領導醫藥控股責任有限公司 | RORγ調節子 |
US20200031753A1 (en) | 2017-04-06 | 2020-01-30 | Boehringer Ingelheim International Gmbh | Cyclopropyl alkyl amines and process for their preparation |
WO2018229155A1 (en) | 2017-06-14 | 2018-12-20 | Astrazeneca Ab | 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators |
CN109206346A (zh) * | 2017-07-01 | 2019-01-15 | 复旦大学 | 叔胺类衍生物或其盐及其制备方法和用途 |
CN107903263B (zh) * | 2017-12-28 | 2019-11-12 | 山东铂源药业有限公司 | 一种帕布昔利布中间体的合成方法 |
JP7351851B2 (ja) | 2018-05-03 | 2023-09-27 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | レチノイド関連オルファン受容体ガンマ(RORγ)のモジュレーターとしてのベンジイミダゾール誘導体およびそれらの医薬品用途 |
JP2022504780A (ja) | 2018-10-18 | 2022-01-13 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 光学活性1-シクロプロピルアルキル-1-アミンのスケーラブルな合成 |
US20230014730A1 (en) | 2019-09-23 | 2023-01-19 | Nanjing Zhengxiang Pharmaceuticals Co., Ltd. | Phosphodiesterase inhibitors and use |
EP4053109A4 (en) | 2019-10-31 | 2022-12-21 | Jiangsu Hengrui Medicine Co., Ltd. | ACID ADDITION SALT BY RORy REGLER |
WO2022106550A1 (en) | 2020-11-19 | 2022-05-27 | Boehringer Ingelheim International Gmbh | Crystalline polymorphic form of a ror gamma inhibitor |
WO2022106548A1 (en) | 2020-11-19 | 2022-05-27 | Boehringer Ingelheim International Gmbh | Solid forms of a ror gamma inhibitor |
WO2022106549A1 (en) | 2020-11-19 | 2022-05-27 | Boehringer Ingelheim International Gmbh | Crystalline salts of a ror gamma inhibitor |
WO2022106547A1 (en) | 2020-11-19 | 2022-05-27 | Boehringer Ingelheim International Gmbh | Process for synthesising a ror gamma inhibitor |
WO2022106551A1 (en) | 2020-11-19 | 2022-05-27 | Boehringer Ingelheim International Gmbh | Co-crystals of a ror gamma inhibitor |
CN117003757A (zh) * | 2022-05-07 | 2023-11-07 | 苏州浦合医药科技有限公司 | 取代的双环杂芳基化合物作为usp1抑制剂 |
WO2023232870A1 (en) | 2022-05-31 | 2023-12-07 | Immunic Ag | Rorg/rorgt modulators for the treatment of virus infections like covid-19 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0102716D0 (sv) * | 2001-08-14 | 2001-08-14 | Astrazeneca Ab | Novel compounds |
WO2009022185A2 (en) * | 2007-08-16 | 2009-02-19 | Astrazeneca Ab | 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use |
CN102227425A (zh) | 2008-09-26 | 2011-10-26 | 贝林格尔·英格海姆国际有限公司 | 作为ccr1受体拮抗剂的氮杂吲唑化合物 |
EP2491028B1 (en) | 2009-10-21 | 2013-12-11 | Boehringer Ingelheim International GmbH | Indazole and pyrazolopyridine compounds as ccr1 receptor antagonists |
US9359361B2 (en) * | 2011-06-01 | 2016-06-07 | Janus Biotherapeutics, Inc. | Immune system modulators |
JP6114820B2 (ja) * | 2012-05-14 | 2017-04-12 | イースト チャイナ ユニバーシティ オブ サイエンス アンド テクノロジー | プテリジノン誘導体およびegfr、blk、flt3の阻害剤としての応用 |
PE20161572A1 (es) * | 2014-04-14 | 2017-02-01 | Boehringer Ingelheim Int | Compuestos como moduladores de ror gamma |
EP3356366B1 (en) * | 2015-10-01 | 2019-08-28 | Boehringer Ingelheim International GmbH | Pteridine derivatives as modulators of ror gamma |
US11358967B2 (en) * | 2016-01-20 | 2022-06-14 | Boehringer Ingelheim International Gmbh | Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma |
-
2015
- 2015-04-10 PE PE2016001963A patent/PE20161572A1/es unknown
- 2015-04-10 PL PL15718330T patent/PL3131902T3/pl unknown
- 2015-04-10 BR BR122020020657-8A patent/BR122020020657B1/pt active IP Right Grant
- 2015-04-10 KR KR1020207010364A patent/KR102410076B1/ko active IP Right Grant
- 2015-04-10 PT PT15718330T patent/PT3131902T/pt unknown
- 2015-04-10 PE PE2020001484A patent/PE20211002A1/es unknown
- 2015-04-10 CA CA2944787A patent/CA2944787C/en active Active
- 2015-04-10 NZ NZ723530A patent/NZ723530A/en unknown
- 2015-04-10 EA EA201890329A patent/EA035063B1/ru not_active IP Right Cessation
- 2015-04-10 SG SG11201608537SA patent/SG11201608537SA/en unknown
- 2015-04-10 AP AP2016009403A patent/AP2016009403A0/en unknown
- 2015-04-10 SI SI201530865T patent/SI3131902T1/sl unknown
- 2015-04-10 EA EA201691978A patent/EA031351B1/ru not_active IP Right Cessation
- 2015-04-10 MX MX2016013342A patent/MX370780B/es active IP Right Grant
- 2015-04-10 MA MA046373A patent/MA46373A/fr unknown
- 2015-04-10 CN CN201580016630.0A patent/CN106132965B/zh active Active
- 2015-04-10 BR BR112016021962A patent/BR112016021962A2/pt not_active IP Right Cessation
- 2015-04-10 UA UAA201803569A patent/UA121255C2/uk unknown
- 2015-04-10 WO PCT/US2015/025328 patent/WO2015160654A1/en active Application Filing
- 2015-04-10 RS RSP20191083 patent/RS59170B1/sr unknown
- 2015-04-10 ES ES15718330T patent/ES2744299T3/es active Active
- 2015-04-10 UA UAA201610804A patent/UA120094C2/uk unknown
- 2015-04-10 HU HUE15718330A patent/HUE045847T2/hu unknown
- 2015-04-10 US US14/683,682 patent/US9242989B2/en active Active
- 2015-04-10 KR KR1020167031654A patent/KR102410069B1/ko active IP Right Grant
- 2015-04-10 AU AU2015247983A patent/AU2015247983B2/en not_active Ceased
- 2015-04-10 MY MYPI2016001598A patent/MY182834A/en unknown
- 2015-04-10 CN CN201710445827.7A patent/CN107266450B/zh active Active
- 2015-04-10 LT LTEP15718330.2T patent/LT3131902T/lt unknown
- 2015-04-10 EP EP18177902.6A patent/EP3418280B1/en active Active
- 2015-04-10 JP JP2016562565A patent/JP6282759B2/ja active Active
- 2015-04-10 ME MEP-2019-233A patent/ME03513B/me unknown
- 2015-04-10 DK DK15718330.2T patent/DK3131902T3/da active
- 2015-04-10 CN CN201710445005.9A patent/CN107266454B/zh active Active
- 2015-04-10 EP EP15718330.2A patent/EP3131902B1/en active Active
- 2015-04-13 UY UY0001036077A patent/UY36077A/es not_active Application Discontinuation
- 2015-04-13 TW TW104111832A patent/TWI655192B/zh not_active IP Right Cessation
- 2015-04-13 AR ARP150101103A patent/AR100058A1/es not_active Application Discontinuation
- 2015-04-13 TW TW107130729A patent/TWI652268B/zh not_active IP Right Cessation
- 2015-11-20 US US14/946,873 patent/US20160075706A1/en not_active Abandoned
-
2016
- 2016-08-22 IL IL247419A patent/IL247419B/en active IP Right Grant
- 2016-09-20 US US15/270,029 patent/US9598415B2/en active Active
- 2016-09-27 CL CL2016002421A patent/CL2016002421A1/es unknown
- 2016-10-11 PH PH12016502019A patent/PH12016502019B1/en unknown
-
2017
- 2017-01-23 HK HK18104174.0A patent/HK1244801A1/zh unknown
- 2017-01-23 HK HK18104172.2A patent/HK1244800A1/zh unknown
- 2017-02-07 US US15/426,208 patent/US20180022749A1/en not_active Abandoned
-
2018
- 2018-01-24 JP JP2018009384A patent/JP6463855B2/ja active Active
- 2018-09-06 US US16/123,139 patent/US20190002465A1/en not_active Abandoned
- 2018-12-20 IL IL26387818A patent/IL263878B/en active IP Right Grant
-
2019
- 2019-04-30 AU AU2019203027A patent/AU2019203027B2/en not_active Ceased
- 2019-09-02 HR HRP20191579 patent/HRP20191579T1/hr unknown
- 2019-09-09 CY CY20191100942T patent/CY1122012T1/el unknown
-
2020
- 2020-02-04 PH PH12020500252A patent/PH12020500252A1/en unknown
- 2020-07-21 AR ARP200102050A patent/AR119454A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY36077A (es) | Derivados de 6-amino-8h-pteridin-7-ona como moduladores de ror gamma y composiciones farmacéuticas que los contienen | |
CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
CL2019001744A1 (es) | Derivados de benzoxazol como inmunomoduladores. | |
CL2018003701A1 (es) | Compuestos heterocíclicos como inmunomoduladores. | |
ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
CL2017001204A1 (es) | Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa | |
DOP2016000144A (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
ECSP19083923A (es) | Inhibidores pirazólicos de magl | |
CL2016003398A1 (es) | Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo. | |
CL2018001569A1 (es) | Compuestos heteroaromáticos como inhibidores de btk | |
ECSP19035077A (es) | Inhibidores de magl | |
ECSP19035377A (es) | Inhibidores de magl | |
CL2019001336A1 (es) | Inhibidores de la magl. | |
CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
CL2020000085A1 (es) | Moduladores de nlrp3. | |
UY35997A (es) | Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
ECSP16074207A (es) | Pirazinas moduladoras de gpr6 | |
CL2019001406A1 (es) | Moduladores de ror gamma (rory). | |
MX2020004871A (es) | Derivados de acido cafeico y sus usos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20230224 |